CSL Behring wins FDA nod for Kcentra
This article was originally published in Scrip
Executive Summary
The US FDA approved CSL Behring's Kcentra (prothrombin complex concentrate, human) as an urgent reversal treatment for vitamin K antagonist (VKA) anticoagulation in adults with acute major bleeding, a condition for which plasma is the only other approved product in the US.